Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2016 - 2025)

Historic Other financing activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Q3 2025 value amounting to $209000.0.

  • Viridian Therapeutics, Inc.\DE's Other financing activities fell 9846.92% to $209000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.7 million, marking a year-over-year decrease of 19827.61%. This contributed to the annual value of $446000.0 for FY2022, which is N/A changed from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Other financing activities stood at $209000.0, which was down 9846.92% from $207000.0 recorded in Q1 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Other financing activities registered a high of $18.1 million during Q3 2022, and its lowest value of -$24.1 million during Q4 2024.
  • Moreover, its 4-year median value for Other financing activities was $209000.0 (2025), whereas its average is $78363.6.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Other financing activities was 449181.82% (2021), while the steepest drop was 24750.84% (2021).
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Other financing activities (Quarter) stood at -$5.3 million in 2021, then crashed by 235.93% to -$17.7 million in 2022, then crashed by 36.34% to -$24.1 million in 2024, then surged by 100.87% to $209000.0 in 2025.
  • Its Other financing activities stands at $209000.0 for Q3 2025, versus $207000.0 for Q1 2025 and -$24.1 million for Q4 2024.